LAS VEGAS, Jan. 4, 2019 /PRNewswire/ -- Digipath, Inc. (OTC-QB: DIGP) a service oriented independent testing laboratory, data acquisition and media firm focused on the developing cannabis and hemp markets, received three more Badges from Emerald Scientific for excellence in proficiency. Emerald Scientific organizes The Emerald Test™, a biannual Inter-Laboratory Comparison Proficiency Test, and the Emerald Badge is considered to be one of the most prestigious independent awards that a cannabis laboratory can receive.
Digipath Labs participated in the Fall 2018 round of proficiency testing for cannabis testing laboratories in three categories: pesticide screening, water activity and residual solvents. Digipath Labs was awarded Emerald Badges for all three tests, adding to the many badges previously awarded to Digipath Labs, including for cannabinoid and terpene analysis, heavy metal screening, and microbiology. Labs receiving a badge are recognized for their capabilities through inter-laboratory comparison (ILC) with their peers.
"Participation in these Emerald Scientific proficiency tests enables us to showcase our commitment to excellence when it comes to accurate test results. I am very proud of these awards and the continual commitment to excellence by the staff at Digipath," stated Todd Denkin, CEO of Digipath. "Clients and consumers can be assured that if their products have been tested by Digipath Labs, the results are accurate."
About Digipath, Inc. (DIGP)
Digipath, Inc., supports the cannabis industry's best practices for reliable testing, data acquisition, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry.
Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client's products through analysis, research, development, and standardization.
Information about Forward-Looking Statements
This press release contains "forward-looking statements" that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company's need for additional funding, the demand for the Company's products, governmental regulation of the cannabis industry, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
SOURCE Digipath, Inc.